Qualigen Therapeutics (NASDAQ:AIXC – Get Free Report) and Endonovo Therapeutics (OTCMKTS:ENDVD – Get Free Report) are both small-cap manufacturing companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, valuation, dividends, institutional ownership, earnings, risk and analyst recommendations.
Valuation & Earnings
This table compares Qualigen Therapeutics and Endonovo Therapeutics”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Qualigen Therapeutics | N/A | N/A | -$6.26 million | ($7.50) | -0.17 |
| Endonovo Therapeutics | $170,000.00 | 0.00 | -$400,000.00 | ($10.00) | N/A |
Profitability
This table compares Qualigen Therapeutics and Endonovo Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Qualigen Therapeutics | N/A | N/A | -52.57% |
| Endonovo Therapeutics | -6,075.54% | N/A | -279.35% |
Volatility and Risk
Qualigen Therapeutics has a beta of 0.34, suggesting that its share price is 66% less volatile than the S&P 500. Comparatively, Endonovo Therapeutics has a beta of 1.98, suggesting that its share price is 98% more volatile than the S&P 500.
Analyst Ratings
This is a summary of current recommendations and price targets for Qualigen Therapeutics and Endonovo Therapeutics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Qualigen Therapeutics | 1 | 0 | 0 | 0 | 1.00 |
| Endonovo Therapeutics | 0 | 0 | 0 | 0 | 0.00 |
Given Endonovo Therapeutics’ higher probable upside, analysts plainly believe Endonovo Therapeutics is more favorable than Qualigen Therapeutics.
Institutional & Insider Ownership
3.2% of Qualigen Therapeutics shares are owned by institutional investors. 1.2% of Qualigen Therapeutics shares are owned by insiders. Comparatively, 5.6% of Endonovo Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Summary
Endonovo Therapeutics beats Qualigen Therapeutics on 6 of the 11 factors compared between the two stocks.
About Qualigen Therapeutics
Qualigen Therapeutics, Inc., a biotechnology company, develops novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a rapid diagnostic testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, a DNA coated gold nanoparticle cancer drug candidate that targets various cancers; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and STARS blood cleansing system, a DNA/RNA-based treatment device that removes tumor-produced compounds and viruses from a patient’s blood. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.
About Endonovo Therapeutics
Endonovo Therapeutics, Inc. is a biotechnology company, which engages in the development of bio-electronic approach to regenerative medicine. The firm also develops, manufactures and distributes evolutionary medical devices focused on the healing of wounds and reduction of pain, edema and inflammation on and in the human body. Its technology and products include Electroceuticals, EFECT Trial, SofPulse, Electroceutical Therapy, and Scientific Studies. The company was founded in November 2008 and is headquartered in Woodland Hills, CA.
Receive News & Ratings for Qualigen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qualigen Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
